Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis
Announces next steps for clinical development plan in severe liver diseasesBOSTON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:...